Allele and antigen-specific treatment of rheumatoid arthritis: A double blind, placebo controlled phase trial

Journal of Rheumatology

Volumn 30, Issue 3, 2003, Pages 449-454

  Kavanaugh, Arthur ^a   Genovese, Mark ^b   Baughman, Jan ^m   Kivitz, Alan ^c   Bulpitt, Ken ^d   Olsen, Nancy ^e   Weisman, Michael ^f   Matteson, Eric ^g   Furst, Daniel ^d   Van Vollenhoven, Ronald ^h   Anderson, James ⁱ   Cohen, Stanley ^j   Wei, Nathan ^k   Meijerink, Jan ^l   Jacobs, Cindy ^m   Mocci, Simonetta ^m  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^c Altoona Center for Clinical Research   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e VANDERBILT UNIVERSITY   (United States)

^f CEDARS SINAI MEDICAL CENTER   (United States)

^g MAYO CLINIC   (United States)

^h KAROLINSKA INSTITUTE   (Sweden)

ⁱ Research Institute of Kansas   (United States)

^j METROPLEX CLINICAL RESEARCH CENTER   (United States)

^k Arthritis and Osteoporosis Center of Maryland   (United States)

^l NV ORGANON   (Netherlands)

^m GLAXOSMITHKLINE   (United States)

more..

Author keywords

Autoantigens; Hla dr antigens; Major histocompatibility complex; Rheumatoid arthritis; T cell antigen receptors; T lymphocytes

Indexed keywords

AG 4263; ANTIBODY; CD4 ANTIGEN; CD8 ANTIGEN; CDP 263; GLYCOPROTEIN GP 39; HLA DR4 ANTIGEN; HYDROXYCHLOROQUINE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; ORG 36601; PREDNISONE; SALAZOSULFAPYRIDINE; UNCLASSIFIED DRUG;

ADULT; AGED; ALLELE; ANTIBODY PRODUCTION; ANTIGEN SPECIFICITY; ARTICLE; CELL COUNT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE EXACERBATION; DOSE CALCULATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INFUSION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; ERYTHEMA; FATIGUE; HUMAN; IMMUNOLOGICAL TOLERANCE; INJECTION; INJECTION PAIN; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; NAUSEA; PHASE 1 CLINICAL TRIAL; PLEURISY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SIDE EFFECT; SKIN BRUISING; SKIN MANIFESTATION; THROMBOPHLEBITIS; UPPER RESPIRATORY TRACT INFECTION;

AGED; ALLELES; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; AUTOANTIGENS; DOUBLE-BLIND METHOD; HLA-DR4 ANTIGEN; HUMANS; MIDDLE AGED; PHENOTYPE; PLACEBOS; PROGNOSIS; RECEPTORS, ANTIGEN, T-CELL; TREATMENT OUTCOME;

EID: 0037334236     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Verheijden GF, Rijnders AWM, Bos E, et al. Human cartilage gp-39 is a key autoantigen in rheumatoid arthritis. Arthritis Rheum 1997;40:1115-25.
2. Joosten LAB, Coenen-de Roo CJJ, Helsen MMA, et al. Induction of tolerance with intranasal administration of human cartilage gp-39 in DBA/1 mice: amelioration of clinical, histologic and radiologic signs of type II collagen-induced arthritis. Arthritis Rheum 2000;43:645-55.
3. Cope AP, Patel SD, Hall F, et al. T cell responses to a human cartilage autoantigen in the context of rheumatoid arthritisassociated and nonassociated HLA-DR4 alleles. Arthritis Rheum 1999;42:1497-507.
4. Cook AD, Stockman A, Brand C, et al. Antibodies to type II collagen and HLA disease susceptibility markers in rheumatoid arthritis. Arthritis Rheum 1999;42:2569-76.
5. Vos K, Steenbakkers P, Miltenburg AMM, et al. Raised human cartilage glycoprotein-39 plasma levels in patients with rheumatoid arthritis and other inflammatory conditions. Ann Rheum Dis 2000;59:544-8.
6. Jenkins MK, Pardoll DM, Mizuguchi J, Quill H, Schwartz R. T cell unresponsiveness in vivo and in vitro: Fine specificity of induction and molecular characterization of the unresponsive state. Immunol Rev 1987;95:113-35.
7. Jenkins M, Schwartz R. Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo. J Exp Med 1987;165:302-19.
8. Mueller D, Jenkins M, Schwartz R. Clonal expansion versus functional clonal inactivation: a costimulatory signaling pathway determines the outcome of T cell antigen receptor occupancy. Ann Rev Immunol 1989;7:445-80.
9. Kennedy, Tan L-T, Dal Canto M, et al. Inhibition of murine relapsing experimental autoimmune encephalomyelitis by immune tolerance to proteolipid protein and its encephalitogenic peptides. J Immunol 1990;144:909-15.
10. Nicolle M, Nag B, Sharma S, et al. Specific tolerance to an acetylcholine receptor epitope induced in vitro in myasthenia gravis CD4-lymphocytes by soluble major histocompatibility complex class II-peptide complexes. J Clin Invest 1994;93:1361-9.
11. Sharma S, Nag B, Su X, et al. Antigen-specific therapy of experimental encephalomyelitis by soluble class II major histocompatibility complex peptide complex. Proc Natl Acad Sci USA 1991;88:11405-9.
12. Spack E, McCutcheon M, Corbelletta N, Nag B, Passmore D, Sharma S. Induction of tolerance in experimental autoimmune myasthenia gravis with solubilized MHC Class II:acetylcholine receptor peptide complexes. J Autoimmun 1995;8:787-807.
13. Deighton C, Walker D, Griffiths I, Roberts D. The contribution of HLA to rheumatoid arthritis. Clin Genet 1989;36:178-82.
14. Nepon G. Major histocompatibility complex-directed susceptibility to rheumatoid arthritis. Adv Immunol 1998;68:315-32.
15. McCutcheon M, Wehner N, Wensky A, et al. A sensitive Elispot assay to detect low-frequency human T lymphocytes. J Immunol Methods 1997;210:149-66.
16. Goodkin DE, Shulman M, Winkelhake J, et al. A phase I trial of solubilized DR2:MBP84-102 (AG284) in multiple sclerosis. Neurology 2000;54:1414-20.
17. Paulus H, Egger M, Ward J, Williams H. Cooperative Systematic Studies of Rheumatic Diseases Group. Analysis of improvement in individual rheumatoid arthritis patients treated with diseasemodifying antirheumatic drugs, based on the findings in patients treated with placebo. Arthritis Rheum 1990;33:477-84.
18. Sharma SD, Nag B, Su XM, et al. Antigen-specific therapy of experimental allergic encephalomyelitis by soluble class II major histocompatibility complex-peptide complexes. Proc Natl Acad Sci USA 1991;88:11465-9.